Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 252-258

  Michou, Laetitia ^a   Brown, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Fibrous dysplasia of bone; Mutation; Osteogenesis imperfecta; Osteopetrosis; Paget's disease of bone

Indexed keywords

ADENOSINE TRIPHOSPHATASE; PLECKSTRIN; TUMOR NECROSIS FACTOR RECEPTOR; UBIQUITIN;

ALBERS SCHOENBERG DISEASE; ALBRIGHT SYNDROME; BLOOD CELL; BONE DENSITY; FIBROUS DYSPLASIA; GENE; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; OSSIFICATION; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PAGET BONE DISEASE; PHENOTYPE; SHORT SURVEY; SOMATIC MUTATION; SQSTM1 GENE;

EID: 79955528315     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.07.010     Document Type: Short Survey

References (39)

1. Helfrich M.H., Hocking L.J. Genetics and aetiology of pagetic disorders of bone. Arch Biochem Biophys 2008, 473:172-182.
2. Rousiere M., Michou L., Cornelis F., et al. Paget's disease of bone. Best Pract Res Clin Rheumatol 2003, 17:1019-1041.
3. Ralston S.H., Langston A.L., Reid I.R. Pathogenesis and management of Paget's disease of bone. Lancet 2008, 372:155-163.
4. Michou L., Collet C., Laplanche J.L., et al. Genetics of Paget's disease of bone. Joint Bone Spine 2006, 73:243-248.
5. Beyens G., Daroszewska A., de Freitas F., et al. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget's disease of bone. J Bone Miner Res 2007, 22:1062-1071.
6. Morissette J., Laurin N., Brown J.P. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006, 21(Suppl. 2):P38-P44.
7. Goode A., Layfield R. Recent advances in understanding the molecular basis of Paget's disease of bone. J Clin Pathol 2010, 63:199-203.
8. Collet C., Michou L., Audran M., et al. Paget's disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res 2007, 22:310-317.
9. Merchant A., Smielewska M., Patel N., et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 2009, 24:484-494.
10. Matthews B.G., Naot D., Bava U., et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009, 94:691-694.
11. Chamoux E., Couture J., Bisson M., et al. The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol Endocrinol 2009, 23:1668-1680.
12. Nakamura K, Kimple AJ, Siderovski DP, et al. PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation. J Biol Chem 2010;285:2077-89.
13. Kurihara N., Hiruma Y., Zhou H., et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007, 117:133-142.
14. Hiruma Y., Kurihara N., Subler M.A., et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008, 17:3708-3719.
15. Weinstein L.S. G(s)alpha mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Miner Res 2006, 21(Suppl. 2):P120-P124.
16. Chapurlat R.D., Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol 2008, 22:55-69.
17. Dumitrescu C.E., Collins M.T. McCune-Albright syndrome. Orphanet J Rare Dis 2008, 3:12.
18. Lumbroso S., Paris F., Sultan C. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. J Clin Endocrinol Metab 2004, 89:2107-2113.
19. Ringel M.D., Schwindinger W.F., Levine M.A. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996, 75:171-184.
20. Lietman S.A., Ding C., Levine M.A. A highly sensitive polymerase chain reaction method detects activating mutations of the GNAS gene in peripheral blood cells in McCune-Albright syndrome or isolated fibrous dysplasia. J Bone Joint Surg Am 2005, 87:2489-2494.
21. Hayward B.E., Moran V., Strain L., et al. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. Proc Natl Acad Sci U S A 1998, 95:15475-15480.
22. Peleg R., Luba A., Eliakim A., et al. McCune-Albright syndrome in a discordant monozygotic twin. Isr Med Assoc J 2009, 11:343-347.
23. Balemans W., Van Wesenbeeck L., Van Hul W. A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 2005, 77:263-264.
24. Del Fattore A., Cappariello A., Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 2008, 42:19-29.
25. Sobacchi C., Frattini A., Guerrini M.M., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
26. Stark Z., Savarirayan R. Osteopetrosis. Orphanet J Rare Dis 2009, 4:5.
27. Tolar J., Teitelbaum S.L., Orchard P.J. Osteopetrosis. N Engl J Med 2004, 351:2839-2849.
28. Van Wesenbeeck L., Cleiren E., Gram J., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
29. Chu K., Koller D.L., Snyder R., et al. Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes. Bone 2005, 37:655-661.
30. Segovia-Silvestre T., Neutzsky-Wulff A.V., Sorensen M.G., et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet 2009, 124:561-577.
31. Van Dijk F.S., Pals G., Van Rijn R.R., et al. Classification of osteogenesis imperfecta revisited. Eur J Med Genet 2009, 53:1-5.
32. Glorieux F.H. Osteogenesis imperfecta. Best Pract Res Clin Rheumatol 2008, 22:85-100.
33. Baujat G., Lebre A.S., Cormier-Daire V., et al. [Ostéogenèse imparfaite, annonce du diagnostic (classification clinique et génétique)]. Arch Pediatr 2008, 15:789-791.
34. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
35. Basel D., Steiner R.D. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med 2009, 11:375-385.
36. van Dijk F.S., Nesbitt I.M., Zwikstra E.H., et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 2009, 85:521-527.
37. Morello R., Bertin T.K., Chen Y., et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006, 127:291-304.
38. Cabral W.A., Chang W., Barnes A.M., et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007, 39:359-365.
39. Cheung M.S., Glorieux F.H. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 2008, 9:153-160.